Commonwealth of Pennsylvania Public School Empls Retrmt SYS Raises Stock Holdings in Zoetis Inc. $ZTS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.6% in the second quarter, Holdings Channel reports. The firm owned 109,190 shares of the company’s stock after acquiring an additional 6,786 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Zoetis were worth $17,028,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. purchased a new position in shares of Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC bought a new position in Zoetis in the first quarter worth approximately $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter worth $29,000. REAP Financial Group LLC lifted its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the period. Finally, NewSquare Capital LLC boosted its stake in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.3%

Shares of ZTS stock opened at $120.78 on Friday. Zoetis Inc. has a twelve month low of $117.26 and a twelve month high of $181.85. The stock has a market cap of $53.23 billion, a P/E ratio of 20.79, a P/E/G ratio of 2.31 and a beta of 0.90. The stock has a 50 day moving average of $140.92 and a 200 day moving average of $151.47. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. JPMorgan Chase & Co. dropped their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Stifel Nicolaus set a $140.00 price objective on shares of Zoetis in a research note on Tuesday, November 4th. Finally, Morgan Stanley cut their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $180.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.